WEBINAR SERIES: Modern medicines series SGLT2 Inhibitors: What we need to know

About the series

Over the first 3 programmes in this series, Professor Cliff Bailey and colleagues provided concise evidence-based guidance to contemporary medications and their application in daily care with the aim of assessing the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications. These can now be viewed on our on-demand page, see below.

Still to come in the series…

SGLT2 inhibitors: All you need to know in 30 minutes

Tuesday 14th December, 19:00 hours

Presenters: Professor Cliff Bailey & Dr Martin Hadley-Brown

A quick ‘bite-size’ update on SGLT2 Inhibitors from the 2021 major congresses. Prof Bailey will provide a quick revision of where we are before updating us on the latest CVD and renal developments while Dr Martin Hadley-Brown will join for the interactive audience discussion to answer questions from a primary care practicality point of view.

The webinar will include:

  • 30 minute ‘bite-size’ session
  • SGLT2 Inhibitors and CV disease: Where we are now (Prof. Bailey)
  • SGLT2 Inhibitors and renal disease: Where we are now (Prof. Bailey)
  • 15 minute Q&A and audience discussion (Prof. Bailey & Dr Hadley-Brown)

To finish the series in 2022…

SGLT2 inhibitors: Translating the Guidelines

(Date tbc) February, 19:00 hours

Presenters: Professor Cliff Bailey & Dr Martin Hadley-Brown tbc

A quick ‘bite-size’ translation of the new Guidelines with focus on the use of SGLT2 Inhibitors, covering the latest ADA/EASD consensus plus the revision of the Primary Care Europe Diabetes Guidelines. Prof Bailey will provide a quick revision of where SGLT2’s sit within the current guidance before Dr Hadley-Brown translates what is new and how this impacts primary care. There will then be an interactive audience discussion to answer questions from primary care.

The webinar will include:

  • 30 minute ‘bite-size’ session
  • SGLT2 Inhibitors: Current guidance (Prof. Bailey)
  • SGLT2 Inhibitors: What is new for primary care (Dr Hadley-Brown)
  • 15 minute Q&A and Audience discussion (Prof. Bailey & Dr Hadley-Brown)

We will notify you in due course when registration for the February date opens.

 


 

Your programme presenters

Professor Cliff Bailey

Emeritus Professor of Clinical Science, Aston University, Birmingham

Professor Vinod Patel

Professor, Diabetes and Clinical Skills,
Warwick Medical School. Honorary
Consultant in Endocrinology and Diabetes, George Eliot Hospital, Nuneaton

Dr Martin Hadley-Brown

FRCGP,
Hughes Hall, University of Cambridge

Dr Pam Brown

GP, SA1 Medical Practice,
Swansea

You can now watch Programmes 1, 2 & 3 on-demand. If you cannot attend any of the live broadcasts, the webinars will be available on-demand 24 hours after the event.

Included in each programme:

  • A one hour webinar including a live Q&A discussion
  • Downloadable slides to print off and keep
  • downloadable factsheet summarising the guidance
  • A case study based CPD learning module with certificate upon completion
 

Programme 1 – Understanding SGLT2 inhibition
Tuesday 9th February, 19.00

Speaker: Professor Cliff Bailey

Type 2 diabetes and SGLT2 inhibitors in context

  1. Type 2 diabetes as a metabolic and cardio-renal disease
  2. Different glucose-lowering therapies
  3. The SGLT2 inhibitor class
  4. Mechanism of SGLT2 inhibition

Speaker: Professor Vinod Patel

Managing glycaemic control and body weight

  1. Glucose control and weight control in RCTs
  2. Real world evidence of efficacy 
  3. Tolerability and safety profiles
  4. Positioning in treatment algorithms for type 2 diabetes

Click below to watch the webinar on-demand.

Watch on-demand now Request a password

This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.


 

Programme 2 – SGLT2 inhibitors and the heart
Tuesday 23rd February, 19.00

Speaker: Professor Cliff Bailey

Effects of SGLT2 inhibitors on cardiovascular function

  1. Cardiovascular disease in type 2 diabetes
  2. SGLT2 inhibitors lower blood pressure
  3. SGLT2 inhibitors reduced heart failure risk
  4. Mechanisms of SGLT2 inhibitors on heart and circulation

Speaker: Dr Martin Hadley-Brown

Role of SGLT2 inhibitors in the management of CV disease

  1. Improve BP control independently of other antihypertensives
  2. Reduce risk of new onset or worsening heart failure 
  3. May benefit atherosclerotic cardiovascular disease
  4. Positioned in algorithms for type 2 diabetes by CV effects

Click below to watch the webinar on-demand.

Watch on-demand now Request a password

This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.


 

Programme 3 – SGLT2 inhibitors and the kidney
Tuesday 9th March, 19.00

Speaker: Professor Cliff Bailey

Reno-protective effects of SGLT2 inhibitors

  1. Kidney disease in type 2 diabetes
  2. SGLT2 inhibitors and glomerular filtration rate
  3. SGLT2 inhibitors reduced albuminuria
  4. Reno-protective mechanisms of SGLT2 inhibitors

Speaker: Dr Pam Brown

SGLT2 inhibitors in the management diabetic kidney disease

  1. Slow decline in glomerular filtration rate
  2. Reduce albuminuria 
  3. Delay progression of CKD without diabetes
  4. Value in prevention and treatment of diabetic kidney disease

Click below to watch the webinar on-demand.

Watch on-demand now Request a password

This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.

 

Don’t forget to share this programme with a colleague click here

 This webinar is supported by Boehringer Ingelheim through an unrestricted educational grant

 

 

 

The content, opinions and statements made in this webinar are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board and no liability is accepted for the consequences of any misleading or inaccurate information.